Showing 321 - 340 results of 15,852 for search '(( significantly ((lower decrease) OR (we decrease)) ) OR ( significantly increased decrease ))', query time: 0.38s Refine Results
  1. 321
  2. 322
  3. 323
  4. 324
  5. 325

    Presentation 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.pptx by Juan Chen (61123)

    Published 2025
    “…</p>Conclusion<p>This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA Bdnf-as.…”
  6. 326
  7. 327

    The strength of the commute time-functional connectivity relationship demonstrates weak pathological significance and weak dependency on age. by Rostam M. Razban (22232522)

    Published 2025
    “…</b> Individuals with mental health disorders have slightly higher average commute times and much lower average FCs. <b>D.</b> Strengthening commute time-FC correlations shown in <b>B</b> seem to be driven by a decrease in average commute time across age. …”
  8. 328
  9. 329
  10. 330
  11. 331
  12. 332

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  13. 333

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  14. 334

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  15. 335
  16. 336
  17. 337
  18. 338
  19. 339
  20. 340

    S8 File - by Martha R. Smith (20410184)

    Published 2024
    Subjects: